Tempest Therapeutics' stock jumps nearly 4,000% as liver-cancer treatment shows promise

Shares of Tempest Therapeutics Inc. TPST, +3972.53% soared nearly 4,000% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.

Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said. Tempest on Wednesday also announced a limited duration stockholder rights plan, or “poison pill,” exercisable only if an entity offers to acquire 10% or more of the company’s outstanding common stock.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promiseOncology company’s board adopts poison-pill plan
Source: MarketWatch - 🏆 3. / 97 Read more »

Akero Therapeutics shares plunge on liver disease treatment's mixed resultsCompany’s lead product candidate shows some benefit for patients with cirrhosis due to fatty liver disease
Source: MarketWatch - 🏆 3. / 97 Read more »

Amgen's cancer-drug pipeline looks promising despite FDA setback, analysts sayStrong oncology, obesity, and cardiovascular drug candidates behind rating upgrade
Source: MarketWatch - 🏆 3. / 97 Read more »